Amylyx Drug Cuts Dangerous Low Blood Sugar Episodes After Weight-Loss Surgery in Key Trial
Amylyx’s avexitide reduced severe low blood sugar episodes by 55% in a Phase 3 trial for post-bariatric hypoglycemia. First potential treatment nears FDA filing.
